Adverse Drug Effects in Patients with CKD: Primum Non Nocere.
Perazella MA, Nolin TD. Adverse Drug Effects in Patients with CKD: Primum Non Nocere. Clinical Journal Of The American Society Of Nephrology 2020, 15: 1075-1077. PMID: 32611663, PMCID: PMC7409750, DOI: 10.2215/cjn.08890620.Peer-Reviewed Original ResearchSGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAcute Kidney InjuryDiabetes Mellitus, Type 2HumansPharmaceutical PreparationsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressure